WCG
FLGT icon

Weaver Consulting Group’s Fulgent Genetics FLGT Stock Holding History

Weaver Consulting Group’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-900
Closed -$36K – 405
2020
Q3 		$36K Buy
900
+200
+29% +$6.26K 0.02% 309
2020
Q2 		$11K Buy
+700
New +$10.7K 0.01% 500

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Weaver Consulting Group's FLGT Position: Q4 2020 in Review

Weaver Consulting Group sold out of Fulgent Genetics (FLGT) in Q4 2020, closing a stake of 900 shares — an estimated $36K sold.

Weaver Consulting Group first reported a position in FLGT in Q2 2020 and held it in 2 quarters. The position peaked at $36K in Q3 2020. 196 funds tracked by Wall St. Rank hold FLGT as of Q4 2020.

  • Weaver Consulting Group reported no remaining Fulgent Genetics position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 900 Fulgent Genetics shares in Q4 2020, an estimated $36K.
  • Weaver Consulting Group first reported a position in Fulgent Genetics in Q2 2020 and held it in 2 quarters.
  • Weaver Consulting Group's Fulgent Genetics position peaked at $36K in Q3 2020.
  • 196 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.